UBC finalizes first global access agreement for a new therapy
Earlier this month, UBC announced that the license agreement for Dr. Kishor Wasan’s new oral formulation of anti-fungal and anti-Leishmania drug Amphotericin B has been finalized. The agreement with iCo Therapeutics Inc. includes mechanisms to promote the availability of the drug in low- and middle-income countries, and is the first global access agreement on a new drug to be executed under UBC’s new global access principles. We at UAEM think that UBC deserves enthusiastic congratulations for its efforts on this project!
Read more in UBC’s press release.
Advertisement
